Melanoma PDX Models
Inotiv offers the Wistar Institute Melanoma (WM) PDX model collection established from targeted therapy relapsed melanoma patients, spanning BRAF inhibitors, BRAK/MEK inhibitors, immune checkpoint inhibitors and targeted therapy and immunotherapy (TT/IT) combinations.
- Vials of cells available
- In vivo propagation
- Efficacy studies
Read about testing second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models in Clinical Cancer Research by Krepler et al.
Further reading:
Xiao et al. (2019). A Melanoma Patient-Derived Xenograft Model. Journal of visualized experiments : JoVE, (147), 10.3791/59508. https://doi.org/10.3791/59508
